Please assess the completion status of the following clinical trial:

Trial Title: Testosterone Plus Finasteride Treatment After Spinal Cord Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male \> 18 years of age~* Traumatic, vascular, or orthopedic spinal cord injury between C2-L3 \>12 months prior to enrollment~* Motor incomplete spinal cord (AIS C/D)~* Ambulatory dysfunction~* Medically stable condition that is asymptomatic for bladder infection, decubiti, cardiopulmonary disease, or other significant medical conditions~* Serum total testosterone (\<325 ng/dL) or bioavailable testosterone (\<70 ng/dL)~Exclusion Criteria:~* Currently participating in another research protocol that may influence study outcomes~* Life expectancy \<1 year~* History of or current congenital spinal cord injury or other degenerative spinal disorder~* Diagnosis of multiple sclerosis, amyotrophic lateral sclerosis, or other neurologic impairment/injury~* History of venous thromboembolism within the last 6 months, specifically deep venous thromboembolism and pulmonary embolism, history of recurrent venous thromboembolism or know hereditary thrombophilia~* Poorly compensated or uncontrolled cardiovascular disease~* Any major cardiovascular event within the last 12 months (defined as a history of acute myocardial infarction, any cardiac revascularization procedure including angioplasty, stenting, or coronary artery bypass grafting, hospitalization due to unstable angina, transient ischemic attack, or stroke)~* Any angina that is not controlled on a current medical regimen (Canadian class II, III, or IV)~* New York Heart Association (NYHA) class III or IV congestive heart failure~* Systolic blood pressure \>160 mmHg or diastolic blood pressure \>100 mm Hg~* Poorly controlled arrhythmia~* Severe valvular disease~* LDL cholesterol \>160 mg/dl with known history of any major cardiovascular event, as defined above, within the last 12 months~* Baseline EKG findings (e.g. left bundle branch block) or marked EKG abnormalities that would preclude serial screening for occult ischemic events~* Current prostate, breast, or other organ cancer~* History of prostate, breast, or other organ cancer, with the exceptions of completely resolved basal or squamous cell carcinoma for a duration of \>24 months or completely resolved melanoma for a duration of \>24 months~* Serum prostate-specific antigen (PSA) \>3.0 ng/ml~* History of benign prostate enlargement (BPE) \>40cc, evaluated via TRUS~* Hematocrit \>47%~* Liver enzymes (AST / ALT) above normal upper limit~* Creatinine \>1.4 mg/dL~* Serum calcium \>10.5 mg/dL~* Gynecomastia~* Mental state that precludes understanding of the protocol~* Diagnosed, but untreated moderate or severe sleep apnea~* Spinal nutrition screening tool score \>15~* Severe claustrophobia that precludes MRI testing~* Current anticoagulant therapy~* Use of any of the following pharmacologic agents in the previous 3 months (testosterone, leuprolide, androgenic hormones, growth hormone, oral androgen precursors, 5-alpha reductase or aromatase inhibitors)~* Use of anti-resorptive or bone anabolic drug therapy in the previous 6 months~* Known allergy to sesame oil

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- testosterone enanthate, finasteride (Type: EXPERIMENTAL): Testosterone enanthate via i.m. injection (125 mg/week) and finasteride orally (5 mg/day)
- placebo treatment (Type: PLACEBO_COMPARATOR): Placebo via i.m. injection (once weekly) and placebo pill orally (daily)

Based on this trial design, predict the completion outcome and termination type (if applicable).